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Surgical resection is the standard approach for patients with early stage 
NSCLC. Even after complete resection, about half of these patients will 
relapse and die within 5 years. Cisplatin-based adjuvant chemotherapy 
has been proven to improve the prognosis for patients with resected 
stages II, IIIA and perhaps some IB 1. In the LACE meta-analysis, the 
pooled hazard ratio was 0.89 (95% CI 0.82-0.96), translating into a 6% 
beneﬁt in 5-year survival (from 43 to 49%) with adjuvant chemother-
apy 2. Postoperative administration of Cisplatin-based chemotherapy, 
however, often results in substantial toxicity, especially after pneumo-
nectomy, and quite some patients are not able to receive it because of 
co-morbidity or postoperative problems 3. Effective and better tolerated 
adjuvant strategies are therefore most welcome.
Cancer immunotherapy might be a good candidate to achieve this goal. 
In a broad sense, cancer immunotherapy is stimulation of the immune 
system to treat cancer. This can be supportive (non-speciﬁc enhance-
ment of innate immune system), passive (supply immune response to 
the system by giving antibodies or cytotoxic T cells), or active by spe-
ciﬁc priming of the immune system to recognize the tumor as foreign. 
Only the last one is cancer vaccination in its true sense.
Conditions for optimal cancer vaccination are: 1/ speciﬁcity (i.e. hav-
ing a well deﬁned target antigen in the tumour, not in other tissues); 2/ 
selectivity (i.e. used in the population expressing the target); 3/ interac-
tion with antigen leads to (more) effective humoral and/or cellular 
response; 4/ tumour must be sensitive to immune killing in order to 
obtain improvement in patient outcome.
A recently reported phase II randomised study with postoperative 
vaccination with the MAGE-A3 vaccine in patients with completely 
resected non-small cell lung cancer (NSCLC) has to be seen in this 
perspective 4.
The postoperative MAGE-A3 approach meets quite some of the condi-
tions listed above. The MAGE-A3 gene is expressed speciﬁcally in 
tumour cells with no expression in normal cells (speciﬁcity). MAGE-
A3 is signiﬁcantly expressed in NSCLC, present in at least 35% of 
intra-operative samples in stages IB, II or IIIA tumours (selectivity) 
5. Pilot studies evaluating the MAGE-A3 cancer immunotherapeutic 
demonstrated humoral and cellular responses, and long-lasting clinical 
objective responses in metastatic melanoma patients 6,7. Moreover, the 
vaccine consists of the MAGE-A3 recombinant protein combined with 
a potent GSK proprietary immunological adjuvant. Therefore, post-
operative immunization with the MAGE-A3 cancer immunotherapeutic 
may be a tumor-speciﬁc, well tolerated, and effective adjuvant therapy.
In this phase II randomised study, patients with completely resected, 
MAGE-A3 positive, pathological stage IB or II NSCLC were randomly 
assigned to postoperative intramuscular administrations of MAGE-
A3 or placebo (2:1 randomisation), with 5 administrations at 3-week 
intervals, followed by 8 administrations every 3 months. Stratiﬁcation 
factors included stage (IB vs. II), histology (squamous carcinoma vs. 
other), and lymph-node procedure (minimal lymph-node sampling 
vs. radical mediastinal lymphadenectomy). The primary endpoint was 
disease-free interval; secondary endpoints were safety, disease-free 
survival, and overall survival.
A total of 1089 surgical tumour specimens were examined by rt-PCR, 
of which 363 expressed the MAGE-A3 gene. Between 01/2002 and 
05/2004, 182 patients (122 stage IB, 60 stage II) from 59 centres in 14 
European countries were randomised. The median age was 63 (45-81), 
87% were males, pathology was 65% squamous cell carcinoma. After a 
median follow-up of 28 months, 67 recurrences were observed. Group 
comparisons of disease-free interval, disease-free survival, and overall 
survival gave respectively a hazard ratio of 0.74 (95%CI 0.44-1.20, 
p=0.107), 0.73 (95%CI 0.45-1.16, p = 0.093) and 0.66 (95%CI 0.36-
1.20, p = 0.088) in favour of the MAGE-A3 group. Overall, treatment 
was well tolerated, with only 3 grade 3 adverse events possibly related 
to the treatment.
As whole, MAGE-A3 cancer immunotherapeutic as adjuvant treatment 
in completely resected Stage IB or II NSCLC was a targeted, well toler-
ated postoperative therapy, with a positive signal for clinical activity in 
the phase II randomised setting (relative improvement in disease-free 
interval and disease-free survival 27%). Further Phase III evaluation in 
early NSCLC is planned for 2007.
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Brain metastases are a common complication of advanced stage non-
small cell lung cancer (NSCLC), with an estimated incidence at initial 
diagnosis of 10-20%, increasing to up to 40% in the two years fol-
lowing diagnosis [Carolan 2005]. Palliative whole brain radiotherapy 
(WBRT) has been the mainstay of treatment for patients with multiple 
brain metastases, extending survival to 3-6 months. However, despite 
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WBRT approximately 50% of patients die with symptoms of intracra-
nial progression. Attempts to increase the treatment efﬁcacy by dose-
escalation of WBRT [Murray 1997], or by focal radiation dose increase 
[Hoskin 1990], have proven unsuccessful. Similarly, the concurrent 
use of radiation sensitizers has failed to result in improved outcome of 
WBRT. Recent studies have focussed on the tolerability and efﬁcacy of 
the combination of WBRT and chemotherapy, e.g. with temozolomide, 
geﬁtinib and erlotinib. However, thus far randomized phase III studies 
are lacking for most chemotherapeutic agents, and available data are 
mostly from phase I/II studies. 
Stereotactic radiosurgery (SRS) is characterized by the high-precision 
delivery of a single fraction of high-dose radiotherapy. SRS techniques 
generate a rapid dose fall-off outside the target volume, thereby sparing 
the normal brain tissue and allowing for high biologically equivalent 
doses to be precisely delivered. SRS is generally considered to be the 
preferred treatment for patients with a limited number (1-3) of brain 
metastases in any location of the brain, including the brainstem. Several 
published series have shown that SRS is highly effective in both single 
and multiple brain metastases, with local control rates of 70-90% and 
median survival rates of between 6 and 12 months being reported. The 
superiority of SRS over WBRT, however, has only been demonstrated 
for patients with a single brain metastasis. A randomized trial has been 
performed by the RTOG, where 333 patients with 1-3 brain metastases 
were assigned to WBRT alone or WBRT plus SRS [Andrews 2004]. 
The overall trial failed to show a signiﬁcant improvement in median 
overall survival, but patients with a single metastasis had improved 
survival (6.5 vs. 4.9 months, p=0.05) and functional autonomy after 
WBRT and SRS.
Although a randomized comparison between neurosurgery and radio-
surgery is lacking, the results of both approaches are comparable and 
SRS is considered to be a non-invasive alternative to surgery, with less 
morbidity and mortality. In recent years, neurosurgery generally has 
been reserved for space-occupying lesions with a diameter of >3 cm, 
and for cases where pathological conﬁrmation is required.
Whether SRS should be delivered as a sole modality or in combination 
with WBRT for primary brain metastases remains a controversial issue. 
The rate of development of new brain metastases after SRS is depen-
dent on the number of brain metastases treated, but also on the quality 
of pre-treatment imaging as high-resolution, double-contrast MRI scans 
can detect additional small metastases in a considerable number of pa-
tients. A multi-institutional study [Sneed 2002] showed that the upfront 
addition of whole brain radiotherapy (WBRT) to SRS decreased the 
intracranial failure rate, but as a result of efﬁcient salvage therapy, this 
failed to have a signiﬁcant impact on the survival of patients. A recently 
reported randomized trial in patients with 1-4 brain metastases has 
conﬁrmed the above ﬁndings [Aoyama 2006], with a 1 year actuarial 
rate of developing new brain metastases of 42% in the WBRT plus 
SRS group and 64% in the SRS-alone group (p=0.003). However, not 
all intracranial relapses were symptomatic and salvage therapy was re-
quired in 15% and 43% of patients after WBRT plus SRS and after SRS 
only, respectively. Furthermore, in the majority of patients salvage SRS 
could be performed, sparing patients from the potential side effects of 
WBRT. In the light of these ﬁndings, most authors advise to use SRS as 
a single modality without upfront WBRT for the primary treatment of 
brain metastases. 
Recent years have witnessed a shift towards more aggressive treatment 
for patients with a synchronous presentation of NSCLC and a single 
brain metastasis. This approach seems particularly valuable for patients 
presenting with a thoracic stage I NSCLC, where combined surgical 
treatment of the brain metastasis and the primary tumor has resulted 
in survival rates that are similar to stage I patients [Billing 2001; Hu 
2006]. The reported high efﬁcacy of stereotactic body radiotherapy 
(SBRT) for early stage NSCLC nowadays allow for a non-invasive, 
but still aggressive treatment regiment in this subset of patients with 
combined SBRT for the primary tumor and SRS for the brain metasta-
sis. The results of such an aggressive approach, however, were far less 
favourable for patients with more advanced thoracic stages.
Radiotherapy facilities for delivering radiosurgery have been increas-
ing rapidly in recent years and the introduction of non-invasive patient 
immobilization techniques, e.g. the use of frameless radiosurgery have 
made SRS a well tolerable, patient-friendly technique that can be per-
formed on an outpatient basis. The toxicity of SRS is only very limited 
with fatigue, and local alopecia being the most commonly encountered 
side effects.
At the VUmc Amsterdam, SRS for patients with primary or recurrent 
brain metastases from NSCLC has been performed since the early 
1990’s. Well over a hundred patients have been treated and the results 
of this series with respect to patterns of failure and toxicity will be 
presented during the meeting.
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Metastasis to the brain is the most common neoplasm of the brain, oc-
curring 25-35% of all cancer patients. Approximately one-half of these 
patients present with a single lesion in the brain. Treatment options for 
patients with single brain metastasis include whole brain irradiation 
(WBI), surgical resection (S), and stereotactic radiosurgery (SRS). Pro-
spective randomized studies that compared S followed by WBI to WBI 
alone found that the addition of surgical resection to WBI improved 
local control and survival. Many studies indicated that SRS achieves 
local control in 80-95% of metastases. With the proven ability of SRS 
to achieve local control, SRS was compared with S with comparable 
outcomes. However, WBI alone appeared to be inferior either to SRS 
